Pacira BioSciences (PCRX) Income towards Parent Company (2010 - 2026)
Pacira BioSciences (PCRX) posted quarterly Income towards Parent Company of $2.9 million for Q1 2026, down 39.4% year-over-year from $4.8 million in Q1 2025, and up 78.13% quarter-over-quarter from $1.6 million in Q4 2025.
Pacira BioSciences (PCRX) Income towards Parent Company (2010 - 2026) Analysis & Trends
Pacira BioSciences' Income towards Parent Company history runs 17 years deep, the most recent figure standing at $2.9 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 39.4% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $5.1 million (up 104.95% YoY), while the FY2025 annual figure was $7.0 million, up 107.07% from the prior year.
- Income towards Parent Company for Q1 2026 stood at $2.9 million, up from $1.6 million in the prior quarter.
- The five-year high for Income towards Parent Company was $25.8 million in Q2 2023, with the low at -$143.5 million in Q3 2024.
- The 5-year median for Income towards Parent Company is $5.4 million (2025), against an average of -$1.9 million.
- The sharpest annual moves came in 2023 and 2024: Income towards Parent Company surged 1666.81% in 2023, then sank 1421.29% in 2024.
- Pacira BioSciences' Income towards Parent Company stood at -$10.1 million in 2022, then surged by 346.19% to $24.9 million in 2023, then tumbled by 35.5% to $16.0 million in 2024, then sank by 89.79% to $1.6 million in 2025, then surged by 78.13% to $2.9 million in 2026.
- Business Quant data shows PCRX's Income towards Parent Company at $2.9 million in Q1 2026, $1.6 million in Q4 2025, and $5.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Pacira BioSciences | 944.33 Mn | 693.29 Mn | 148.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.65 Mn |
| Mar 31, 2026 | 2.92 Mn |
| Dec 31, 2025 | 1.64 Mn |
| Sep 30, 2025 | 5.43 Mn |
| Jun 30, 2025 | -4.85 Mn |
| Mar 31, 2025 | 4.81 Mn |
| Dec 31, 2024 | 16.04 Mn |
| Sep 30, 2024 | -143.47 Mn |
| Jun 30, 2024 | 18.89 Mn |
| Mar 31, 2024 | 8.98 Mn |
| Dec 31, 2023 | 24.87 Mn |
| Sep 30, 2023 | 10.86 Mn |
| Jun 30, 2023 | 25.76 Mn |
| Mar 31, 2023 | -19.54 Mn |
| Dec 31, 2022 | -10.10 Mn |
| Sep 30, 2022 | -693,000.00 |
| Jun 30, 2022 | 19.88 Mn |
| Mar 31, 2022 | 6.83 Mn |
| Dec 31, 2021 | -5.13 Mn |
| Sep 30, 2021 | 17.66 Mn |